• LAST PRICE
    21.74
  • TODAY'S CHANGE (%)
    0.00 (0.00%)
  • Bid / Lots
    21.34/ 1
  • Ask / Lots
    21.47/ 1
  • Open / Previous Close
    0.00 / 21.74
  • Day Range
    ---
  • 52 Week Range
    Low 18.12
    High 32.67
  • Volume
    1
  • Overall Morningstar Rating
    Please Note: Not Ratedout of 3652 funds

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table
TimeVolumeZGEN
Data delayed at least 15 minutes.
Asset Class
Asset Class
US Equity
71.7%
Int'l Equity
27.9%
CDN Equity
0.2%
Cash
0.2%
Fixed Income
0
Other
0.0%
Sectors
Sectors
Healthcare99.8%
Consumer Defensive0.1%
Basic Mat.0
Communication Services0
Consumer Cyclical0
Energy0
Financial Serv.s0
Industrials0
Real Estate0
Technology0
Utilities0
Geographic Region
Geographic Region
United States
71.8%
Europe
6.0%
Asia/Oceania
1.3%
Canada
0.2%
Latin America
0.0%
Africa
0
As of 2022-06-30
Top 10 Holdings
Company Name sortablePosition sortableAllocation sortable
Allocation
1 Month Change
sortable
Market Value sortable
CanadaWuXi Biologics (Cayman) Inc
Long
6.5%
+21.88%
$396.3K
United StatesVRTX
Vertex Pharmaceuticals Inc
Long
5.5%
+22.89%
$338.8K
CanadaLonza Group Ltd
Long
5.0%
+25.35%
$305.4K
United StatesTMO
Thermo Fisher Scientific Inc
Long
4.9%
+22.66%
$302.8K
United StatesABT
Abbott Laboratories
Long
4.9%
+25.52%
$302.6K
CanadaRoche Holding AG
Long
4.9%
+22.69%
$302.1K
United StatesMRNA
Moderna Inc
Long
4.9%
+19.10%
$298.1K
United StatesILMN
Illumina Inc
Long
3.9%
+26.87%
$242.1K
United StatesIQV
IQVIA Holdings Inc
Long
3.9%
+25.51%
$241.9K
United StatesA
Agilent Technologies Inc
Long
3.6%
+26.43%
$219.4K
As of 2022-08-19

Reports

No reports available

Morningstar Ratings

Morningstar Ratings Table
Time HorizonStar Rating
Overall RatingPlease Note: Not Rated
3 Year RatingPlease Note: Not Rated
5 Year RatingPlease Note: Not Rated
10 Year RatingPlease Note: Not Rated
As of 2022-07-31

Past performance is no guarantee of future results. The ratings reflect historical risk-adjusted performance, and the overall rating is derived from a weight average of the fund's 3, 5, and 10 year (Morningstar Rating) metrics.

Style Box is calculated only using the long position holdings of the portfolio.

ETF Profile
Best Fit Index
MSCI ACWI IMI GENOMIC INNOVATION NR USD
Category
Sponsor
BMO Asset Management Inc
Inception
January 26, 2021
As of 2022-06-30

BMO MSCI Genomic Innovation ETF seeks to replicate, to the extent possible, the performance of an innovative genomic companies index, net of expenses. Currently, BMO MSCI Genomic Innovation ETF seeks to replicate the performance of the MSCI ACWI IMI Genomic Innovations Index.

Holding Details
Total Net Assets$6.6M
Shares Out.259.0K
Net Asset Value (NAV)$21.75
Prem/Discount to NAV0.60%
P/E Ratio17.6
Dividend Yield0.09%
Dividend per Share0.02 CAD
Ex-Dividend Date12/29/2021
Dividend Payment Date01/5/2022
Beta---
Morningstar Investment StyleGlobal Equity
Equity Style
Mid Cap Growth
Credit Quality / Duration
---
Fees & Expenses
Actual Management Fee0.40%
Actual Mgmt. Expense Ratio (MER)0.45%